《美股》阿斯利康(AZN.US)首季核心每股盈利胜预期 维持全年盈收预测

阿斯达克财经
Apr 29

英国药厂阿斯利康(AZN.US)  首季核心每股盈利为2.58美元,高于市场预期的2.55美元,收入增长8%至152.88亿美元,受惠于抗癌药物及罕见病药物,有双位数增长。当中,乳癌药物Enhertu收入为8.31亿美元,远高于分析师预期的3.24亿美元。阿斯利康重申以固定汇率计算,全年收入将录得中至高单位数的增长,核心每股盈利预计将录得低双位数增长。(mn/da)(美股为即时串流报价; OTC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10